M. AfodunA, D. EzeE, K. QuadriK, O. MuhammedA, A. MasudM., K. LawalS, O. BuhariM, O. AyindeT
Complex breast masses may appear as suspicious ultrasound findings that usually warrant biopsy. Ductal cell carcinoma in-situ (DCIS) is a form of breast cancer with a non-uniform appearance and malignant potential. A longitudinal review of mammary gland ultrasound (with high frequency transducer) within a three-year period was conducted. Differential diagnosis of fibroadenoma, lactating adenoma, mastitis, galactocele, breast cancer, abscess and “general” masses greater than 16 mm in diameter was stratified. Based on the breast imaging reporting in data system (BIRADS), lesions were classified as benign or malignant and recommendations of cytology made in cases of observed overlap findings. Image sonomorphologic information on mass-echogenic halo and non-uniform orientation were documented; while malignant factors like scar tissue, focal fibrosis and papillomas may be associated with a false positive (conclusion) result. Doppler studies on further mass evaluation is encouraged.
{"title":"Comparative sonographic review of benign and malignant breast masses","authors":"M. AfodunA, D. EzeE, K. QuadriK, O. MuhammedA, A. MasudM., K. LawalS, O. BuhariM, O. AyindeT","doi":"10.5430/JST.V8N1P42","DOIUrl":"https://doi.org/10.5430/JST.V8N1P42","url":null,"abstract":"Complex breast masses may appear as suspicious ultrasound findings that usually warrant biopsy. Ductal cell carcinoma in-situ (DCIS) is a form of breast cancer with a non-uniform appearance and malignant potential. A longitudinal review of mammary gland ultrasound (with high frequency transducer) within a three-year period was conducted. Differential diagnosis of fibroadenoma, lactating adenoma, mastitis, galactocele, breast cancer, abscess and “general” masses greater than 16 mm in diameter was stratified. Based on the breast imaging reporting in data system (BIRADS), lesions were classified as benign or malignant and recommendations of cytology made in cases of observed overlap findings. Image sonomorphologic information on mass-echogenic halo and non-uniform orientation were documented; while malignant factors like scar tissue, focal fibrosis and papillomas may be associated with a false positive (conclusion) result. Doppler studies on further mass evaluation is encouraged.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"1 1","pages":"42"},"PeriodicalIF":0.0,"publicationDate":"2018-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84369275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Win, N. Blocher, W. Tester, Serge Ginzburg, L. Pomo
Objective: To describe a patient with isolated symptomatic pituitary metastasis from Renal Cell Carcinoma (RCC) in a horseshoe kidney. Case report: We report a case of 56-year-old man with RCC of a horseshoe kidney with symptomatic isolated pituitary gland metastasis. He initially presented to us for evaluation of a sellar mass. He complained of fatigue, 50-pound weight loss, anorexia, constipation and nonspecific abdominal pain for 4 months. CT head showed 2.6 cm × 1.8 cm × 2.5 cm sellar mass likely with bilateral cavernous sinus extension. Pituitary function evaluation revealed panhypopituitarism. CT abdomen/pelvis for the evaluation of abdominal pain showed 12.1 cm solid mass in the right renal moiety of a horseshoe kidney. Hydrocortisone and levothyroxine therapy led to cessation of weight loss, but unmasked diabetes insipidus requiring desmopressin therapy. Right heminephrectomy confirmed RCC. Soon after he complained of progressively worsening headache and visual disturbance. Histopathology from urgent trans-sphenoidal hypophysectomy revealed RCC. The patient began post-surgical radiotherapy, but eventually he declined further treatments. In the end, he was placed on hospice where he passed away. Conclusion: Symptomatic pituitary metastasis from RCC are rare and most of those occur in the setting of diffuse metastatic disease. They typically mimic signs and symptoms of non-functioning macroadenomas. They can be synchronous, metachronous or even the presenting lesion of the primary tumor. A pituitary mass in the setting of malignancy should raise suspicion for metastatic disease even though it is extremely rare.
目的:报道一例马蹄形肾肾细胞癌(RCC)分离性有症状的垂体转移。病例报告:我们报告一例56岁男性马蹄肾肾细胞癌伴症状性孤立性垂体转移。他最初给我们做了一个鞍状肿块的评估。他主诉疲劳、体重减轻50磅、厌食、便秘和非特异性腹痛4个月。头颅CT示2.6 cm × 1.8 cm × 2.5 cm鞍区肿块，可能伴双侧海绵窦延伸。垂体功能评估显示全垂体功能低下。腹部/骨盆CT评估腹痛显示马蹄肾右肾部12.1 cm实性肿块。氢化可的松和左旋甲状腺素治疗导致体重减轻的停止，但发现尿崩症需要去氨加压素治疗。右半脑切除术证实肾细胞癌。不久之后，他抱怨头痛和视力障碍逐渐加重。经蝶窦下丘脑切开术的组织病理学显示为肾细胞癌。患者开始术后放疗，但最终拒绝进一步治疗。最后，他被安置在临终关怀医院，在那里去世了。结论:有症状的垂体转移罕见，多发生于弥漫性转移。它们典型地模仿无功能大腺瘤的体征和症状。它们可以是同步的，也可以是异时性的，甚至可以是原发肿瘤的呈现病变。恶性肿瘤背景下的垂体肿块应引起转移性疾病的怀疑，即使它是极其罕见的。
{"title":"Isolated pituitary metastasis from renal cell carcinoma in a horseshoe kidney","authors":"K. Win, N. Blocher, W. Tester, Serge Ginzburg, L. Pomo","doi":"10.5430/JST.V8N1P37","DOIUrl":"https://doi.org/10.5430/JST.V8N1P37","url":null,"abstract":"Objective: To describe a patient with isolated symptomatic pituitary metastasis from Renal Cell Carcinoma (RCC) in a horseshoe kidney. Case report: We report a case of 56-year-old man with RCC of a horseshoe kidney with symptomatic isolated pituitary gland metastasis. He initially presented to us for evaluation of a sellar mass. He complained of fatigue, 50-pound weight loss, anorexia, constipation and nonspecific abdominal pain for 4 months. CT head showed 2.6 cm × 1.8 cm × 2.5 cm sellar mass likely with bilateral cavernous sinus extension. Pituitary function evaluation revealed panhypopituitarism. CT abdomen/pelvis for the evaluation of abdominal pain showed 12.1 cm solid mass in the right renal moiety of a horseshoe kidney. Hydrocortisone and levothyroxine therapy led to cessation of weight loss, but unmasked diabetes insipidus requiring desmopressin therapy. Right heminephrectomy confirmed RCC. Soon after he complained of progressively worsening headache and visual disturbance. Histopathology from urgent trans-sphenoidal hypophysectomy revealed RCC. The patient began post-surgical radiotherapy, but eventually he declined further treatments. In the end, he was placed on hospice where he passed away. Conclusion: Symptomatic pituitary metastasis from RCC are rare and most of those occur in the setting of diffuse metastatic disease. They typically mimic signs and symptoms of non-functioning macroadenomas. They can be synchronous, metachronous or even the presenting lesion of the primary tumor. A pituitary mass in the setting of malignancy should raise suspicion for metastatic disease even though it is extremely rare.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"51 1","pages":"37"},"PeriodicalIF":0.0,"publicationDate":"2018-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85165025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nektarios Koufopoulos, K. Kapatou, F. Antoniadou, D. Nasikas, I. Karaitianos, S. Kokkali, D. Nasi, L. Khaldi
A 61-year-old female patient with no previous medical history presented to our hospital with a palpable right breast mass as well as palpable axillary lymph nodes. Microscopic examination revealed a bifocal primary carcinoma of the breast displaying characteristics similar to that of follicular variant of papillary thyroid carcinoma. Three axillary lymph nodes contained metastases. Immunohistochemical study for TTF-1, Thyroglobulin, GATA-3, ER and PR was consistent with a primary breast carcinoma, excluding the possibility of a metastatic tumor. The above unusual morphological features were caused by improper fixed tissue. Suboptimal fixation may cause tissue artifacts such as shrinkage, streaming, diffusion, vacuolation and nuclear or cytoplasmic changes as well as decreasing tissue antigenicity. Occasionally, altered morphology may mislead to major diagnostic pitfall.
{"title":"Primary breast carcinoma with features of the follicular variant of papillary thyroid carcinoma","authors":"Nektarios Koufopoulos, K. Kapatou, F. Antoniadou, D. Nasikas, I. Karaitianos, S. Kokkali, D. Nasi, L. Khaldi","doi":"10.5430/JST.V8N1P32","DOIUrl":"https://doi.org/10.5430/JST.V8N1P32","url":null,"abstract":"A 61-year-old female patient with no previous medical history presented to our hospital with a palpable right breast mass as well as palpable axillary lymph nodes. Microscopic examination revealed a bifocal primary carcinoma of the breast displaying characteristics similar to that of follicular variant of papillary thyroid carcinoma. Three axillary lymph nodes contained metastases. Immunohistochemical study for TTF-1, Thyroglobulin, GATA-3, ER and PR was consistent with a primary breast carcinoma, excluding the possibility of a metastatic tumor. The above unusual morphological features were caused by improper fixed tissue. Suboptimal fixation may cause tissue artifacts such as shrinkage, streaming, diffusion, vacuolation and nuclear or cytoplasmic changes as well as decreasing tissue antigenicity. Occasionally, altered morphology may mislead to major diagnostic pitfall.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"31 1","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2018-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91086526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Hendawy, Afaf T. Ibrahiem, El-Nagdy Sy, W. Zedan
Background: Epithelial-mesenchymal transition (EMT) is regarded as an essential step for tumor invasion and metastasis. In squamous cell carcinoma of head and neck (HNSCC), N-Cadherin expression and its involvement in tumor progression remains a controversial topic. Aim of the study: The present study aimed to assess the expression of N-cadherin and HA in HNSCC and further study their relation to patients survival and outcomes. Material and methods: Fifty-eight retrospective selected cases of head and neck squamous carcinomas (HNSCCs) with available paraffin blocks. Complete clinico-pathological and follow-up data were recorded. Immune staining for N-cadherin and hyaluronan were done, also, we study the correlation of the results with patients survival data. Results: Squamous cell carcinoma islands demonstrated high N-cadherin expression in 55.2% and low expression in 44.8%. N-cadherin high expression was significantly ( p < .05) associated with large tumor sizes, advanced TNM clinical stage, increased incidence of recurrence and patient’s death. A significant correlation was recorded between the presence of neural invasion and N-cadherin expression ( p = .004). Strong intensity of stromal HA was significantly ( p < .05) associated with an oral site, nodal metastasis, and higher TNM stage. Patients with high N-cadherin expression, diffuse hyaluronan, and strong stromal hyaluronan reaction had significantly lower DFS rates ( p < .05). High N-cadherin expression, diffuse hyaluronan immunoreactivity, and strong stromal hyaluronan reaction intensity had significantly lower OS rates ( p < .05). Conclusion: N-cadherin and hyaluronan could be important and promising biomarkers during surveillance of patients with HNSCC.
{"title":"N-cadherin and hyaluronan expression in head and neck squamous cell carcinoma, relation to patient outcomes","authors":"H. Hendawy, Afaf T. Ibrahiem, El-Nagdy Sy, W. Zedan","doi":"10.5430/JST.V8N1P19","DOIUrl":"https://doi.org/10.5430/JST.V8N1P19","url":null,"abstract":"Background: Epithelial-mesenchymal transition (EMT) is regarded as an essential step for tumor invasion and metastasis. In squamous cell carcinoma of head and neck (HNSCC), N-Cadherin expression and its involvement in tumor progression remains a controversial topic. Aim of the study: The present study aimed to assess the expression of N-cadherin and HA in HNSCC and further study their relation to patients survival and outcomes. Material and methods: Fifty-eight retrospective selected cases of head and neck squamous carcinomas (HNSCCs) with available paraffin blocks. Complete clinico-pathological and follow-up data were recorded. Immune staining for N-cadherin and hyaluronan were done, also, we study the correlation of the results with patients survival data. Results: Squamous cell carcinoma islands demonstrated high N-cadherin expression in 55.2% and low expression in 44.8%. N-cadherin high expression was significantly ( p < .05) associated with large tumor sizes, advanced TNM clinical stage, increased incidence of recurrence and patient’s death. A significant correlation was recorded between the presence of neural invasion and N-cadherin expression ( p = .004). Strong intensity of stromal HA was significantly ( p < .05) associated with an oral site, nodal metastasis, and higher TNM stage. Patients with high N-cadherin expression, diffuse hyaluronan, and strong stromal hyaluronan reaction had significantly lower DFS rates ( p < .05). High N-cadherin expression, diffuse hyaluronan immunoreactivity, and strong stromal hyaluronan reaction intensity had significantly lower OS rates ( p < .05). Conclusion: N-cadherin and hyaluronan could be important and promising biomarkers during surveillance of patients with HNSCC.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"42 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2017-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79425412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ameloblastic carcinoma (AC) is a relatively rare tumor which accounts for less than 4% of odontogenic tumors. The mandible is the preferred site and occurrence in the maxilla is extremely rare. Here, we report the case of a 40-year-old male with maxillary AC and present a review of the reported cases from 2009 to 2017 in English literature.
{"title":"Ameloblastic carcinoma of the maxilla: A rare case presentation and a review of new cases","authors":"S. Sargolzaei, Arash Khaleghjoo, N. Taghavi","doi":"10.5430/JST.V8N1P15","DOIUrl":"https://doi.org/10.5430/JST.V8N1P15","url":null,"abstract":"Ameloblastic carcinoma (AC) is a relatively rare tumor which accounts for less than 4% of odontogenic tumors. The mandible is the preferred site and occurrence in the maxilla is extremely rare. Here, we report the case of a 40-year-old male with maxillary AC and present a review of the reported cases from 2009 to 2017 in English literature.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"17 1","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2017-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84700893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Soft tissue chondroma is a benign cartilaginous neoplasm composed of cells with a chondroid phenotype. Chondromas of soft tissue can have variable histological appearances including deposition of calcium, histiocytic reaction, ossification, and myxoid change. One notable variation is the presence of histological features reminiscent of chondroblastoma of the bone, and the term used in this scenario is chondroblastoma-like chondroma of soft tissue. There have been fourteen previous case reports of chondroblastoma-like chondroma of soft tissue, predominantly in the hands; with one case being reported in the base of the skull. We report two cases of chondroblastoma-like chondroma of soft tissue occurring in the hand and foot. To the best of our knowledge this is the first reported case of chondroblastoma-like chondroma of soft tissue in the foot.
{"title":"Chondroblastoma-like chondroma of soft tissue: A report of two cases","authors":"D. Zaccarini, Z. Badar, A. Valente, G. D. Roza","doi":"10.5430/JST.V8N1P10","DOIUrl":"https://doi.org/10.5430/JST.V8N1P10","url":null,"abstract":"Soft tissue chondroma is a benign cartilaginous neoplasm composed of cells with a chondroid phenotype. Chondromas of soft tissue can have variable histological appearances including deposition of calcium, histiocytic reaction, ossification, and myxoid change. One notable variation is the presence of histological features reminiscent of chondroblastoma of the bone, and the term used in this scenario is chondroblastoma-like chondroma of soft tissue. There have been fourteen previous case reports of chondroblastoma-like chondroma of soft tissue, predominantly in the hands; with one case being reported in the base of the skull. We report two cases of chondroblastoma-like chondroma of soft tissue occurring in the hand and foot. To the best of our knowledge this is the first reported case of chondroblastoma-like chondroma of soft tissue in the foot.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"1 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2017-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88837812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The objective of this study was to determine if adiponectin and IGF-1 salivary concentrations are altered in combination with the presence of obesity and breast cancer. The null hypothesis is that there are no significant adiponectin and IGF-1 concentration alterations secondary to the presence of obesity and/or carcinoma of the breast. Methods: There were two groups of test subjects: healthy controls (n = 20) and individuals diagnosed with breast cancer (n = 20). The two cohorts were further stratified into four groups. These included subjects who are healthy and of normal BMI (n = 10); are healthy but have an elevated BMI (n = 10); have breast cancer and a normal BMI (n = 10); and have cancer and an elevated BMI (n = 10). The presence and concentration of adiponectin and IGF-1 was determined using the ELISA methodology. Results: The investigation revealed a significant increase in mean adiponectin levels in subjects with cancer compared to the controls (t = -2.57; p < .01). Individuals that were diagnosed with breast cancer and were obese exhibited the highest concentrations (F = 5.13; p < .005) of adiponectin. Adiponectin concentrations were also found to be correlated to IGF-I levels (r = 0.05; p < .001). Conclusion: Salivary adiponectin levels were significantly higher among cancer group. There were no significant differences between the cancer and control groups for IGF-I levels.
{"title":"Relationship between salivary adiponectin, IGF-1, obesity and breast cancer","authors":"C. Streckfus","doi":"10.5430/JST.V8N1P1","DOIUrl":"https://doi.org/10.5430/JST.V8N1P1","url":null,"abstract":"Objective: The objective of this study was to determine if adiponectin and IGF-1 salivary concentrations are altered in combination with the presence of obesity and breast cancer. The null hypothesis is that there are no significant adiponectin and IGF-1 concentration alterations secondary to the presence of obesity and/or carcinoma of the breast. Methods: There were two groups of test subjects: healthy controls (n = 20) and individuals diagnosed with breast cancer (n = 20). The two cohorts were further stratified into four groups. These included subjects who are healthy and of normal BMI (n = 10); are healthy but have an elevated BMI (n = 10); have breast cancer and a normal BMI (n = 10); and have cancer and an elevated BMI (n = 10). The presence and concentration of adiponectin and IGF-1 was determined using the ELISA methodology. Results: The investigation revealed a significant increase in mean adiponectin levels in subjects with cancer compared to the controls (t = -2.57; p < .01). Individuals that were diagnosed with breast cancer and were obese exhibited the highest concentrations (F = 5.13; p < .005) of adiponectin. Adiponectin concentrations were also found to be correlated to IGF-I levels (r = 0.05; p < .001). Conclusion: Salivary adiponectin levels were significantly higher among cancer group. There were no significant differences between the cancer and control groups for IGF-I levels.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"85 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2017-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76806272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Streckfus, Daniel Arreola, C. Streckfus, L. Bigler
Objective: The objective of this study is to determine the effects of p1978 on the growth rate of a triple receptor negative breast cancer cell line. Methods: Three cell lines, 185B5 normal tissue, HCC38, and AU585, were seeded with peptide p1978. Corresponding plates were seeded with PBS to serve as controls. Baseline line cell counts were taken at 30% confluence prior to seeding. Counts were again made 48 hours later. Results: The HCC38 cell line showed decreased growth when exposed to the low and high dose of p1978 peptide. Conclusion: The results suggest that p1978 may have potential in treating triple receptor negative breast cancer.
{"title":"Salivary proline rich peptide decreases cell growth in HCC38 triple negative breast cancer cell line","authors":"C. Streckfus, Daniel Arreola, C. Streckfus, L. Bigler","doi":"10.5430/JST.V7N2P38","DOIUrl":"https://doi.org/10.5430/JST.V7N2P38","url":null,"abstract":"Objective: The objective of this study is to determine the effects of p1978 on the growth rate of a triple receptor negative breast cancer cell line. Methods: Three cell lines, 185B5 normal tissue, HCC38, and AU585, were seeded with peptide p1978. Corresponding plates were seeded with PBS to serve as controls. Baseline line cell counts were taken at 30% confluence prior to seeding. Counts were again made 48 hours later. Results: The HCC38 cell line showed decreased growth when exposed to the low and high dose of p1978 peptide. Conclusion: The results suggest that p1978 may have potential in treating triple receptor negative breast cancer.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"31 1","pages":"38"},"PeriodicalIF":0.0,"publicationDate":"2017-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88721238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meningioma is common intracranial benign tumour, but may be diagnosed only at autopsy in developing countries. We present a 38-year-old woman with progressively worsening headache of 7 years duration, who had sudden onset of inability to walk, vomiting and loss of consciousness. She died shortly on admission at the Tamale Teaching Hospital emergency unit. Autopsy conducted found an encapsulated left cerebral hemisphere convexity tumour that had eroded the skull with extension onto the scalp as a swelling. Histological examination confined the tumour to WHO grade I, meningioma.
{"title":"Benign meningioma with complete erosion of the skull in a 38-year-old Ghanaian woman","authors":"E. Der, R. Mikdad, B. J. Leuri, A. Adam","doi":"10.5430/JST.V7N2P34","DOIUrl":"https://doi.org/10.5430/JST.V7N2P34","url":null,"abstract":"Meningioma is common intracranial benign tumour, but may be diagnosed only at autopsy in developing countries. We present a 38-year-old woman with progressively worsening headache of 7 years duration, who had sudden onset of inability to walk, vomiting and loss of consciousness. She died shortly on admission at the Tamale Teaching Hospital emergency unit. Autopsy conducted found an encapsulated left cerebral hemisphere convexity tumour that had eroded the skull with extension onto the scalp as a swelling. Histological examination confined the tumour to WHO grade I, meningioma.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"71 1","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2017-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88477342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Vidal, N. Vontela, Mary M Chen, J. Ryder, Shruti N Sheth, E. Guardino
Background: The use of HER2 targeting therapy has revolutionized the treatment of HER2 positive breast cancers. Here, we investigate whether a sequential approach to dual HER2 blockade of lapatinib followed by trastuzumab will result in improved clinical outcomes. Methods: This was a single institution, open label, single arm, phase II trial in women with HER2 positive breast cancer. Volunteers were treated with sequential neoadjuvant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) for 4 cycles followed by docetaxel (100 mg/m2) concurrent with lapatinib (1,250 mg) (TL) daily for 21 days for four cycles before definitive surgery. The primary end point was pathologic complete response (pCR). Results: The study accrued only 21 of the 71 planned patients from 2/28/2007 to 5/25/2010. All patients (100%) experienced down staging. The pCR rate was 41% (7/18). 11 patients had tumor size of T3 or greater, 3 of which experienced pCR and only 1 underwent breast conservation (lumpectomy). The most common hematologic AE (all grades) was anemia 17/21 (81%). There were no incidences of grade 3 or 4 anemia. 10 of 21 (48%) patients experience a non-hematologic grade 3 AE. The most common non-hematologic AEs (all grades) were irregular menses 20/21 (95%) and hand-foot-skin reactions 20/21 (95%). No increase cardiac abnormalities were noted. The DFS at data cut off was 87.5%. Conclusion: The provocative pCR and DFS results in this high risk locally advanced patient population should be viewed with caution given results of the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study (ALTTO) clinical trial.
{"title":"A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers","authors":"G. Vidal, N. Vontela, Mary M Chen, J. Ryder, Shruti N Sheth, E. Guardino","doi":"10.5430/JST.V7N2P28","DOIUrl":"https://doi.org/10.5430/JST.V7N2P28","url":null,"abstract":"Background: The use of HER2 targeting therapy has revolutionized the treatment of HER2 positive breast cancers. Here, we investigate whether a sequential approach to dual HER2 blockade of lapatinib followed by trastuzumab will result in improved clinical outcomes. Methods: This was a single institution, open label, single arm, phase II trial in women with HER2 positive breast cancer. Volunteers were treated with sequential neoadjuvant doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) for 4 cycles followed by docetaxel (100 mg/m2) concurrent with lapatinib (1,250 mg) (TL) daily for 21 days for four cycles before definitive surgery. The primary end point was pathologic complete response (pCR). Results: The study accrued only 21 of the 71 planned patients from 2/28/2007 to 5/25/2010. All patients (100%) experienced down staging. The pCR rate was 41% (7/18). 11 patients had tumor size of T3 or greater, 3 of which experienced pCR and only 1 underwent breast conservation (lumpectomy). The most common hematologic AE (all grades) was anemia 17/21 (81%). There were no incidences of grade 3 or 4 anemia. 10 of 21 (48%) patients experience a non-hematologic grade 3 AE. The most common non-hematologic AEs (all grades) were irregular menses 20/21 (95%) and hand-foot-skin reactions 20/21 (95%). No increase cardiac abnormalities were noted. The DFS at data cut off was 87.5%. Conclusion: The provocative pCR and DFS results in this high risk locally advanced patient population should be viewed with caution given results of the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation study (ALTTO) clinical trial.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"17 1","pages":"28"},"PeriodicalIF":0.0,"publicationDate":"2017-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88580241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：